Pall Breathing Filters Validated as a Prion Transmission Barrier; Eases Growing Concern About Transmission of variant CJD During Anesthesia Procedures.

Business Editors/Health/Medical Writers

EAST HILLS, N.Y.--(BUSINESS WIRE)--Jan. 14, 2004

The first patient death from variant Creutzfeldt-Jacob Disease (vCJD, the human form of "mad cow disease") as a possible result of a blood transfusion has raised new concerns about the potential transmission of prions during other medical procedures. One area of concern is in the use of respiratory equipment between patients during anesthesia procedures. Studies show that up to 80 percent of anesthetic intubation procedures involve the presence of secreted blood. Pall Corporation (NYSE: PLL) released today the results of a new study showing that one of its breathing system filters, used in anesthesia endotracheal intubation procedures, acts as a barrier against infectious prions. The study, presented at the scientific meeting of the Association of Anaesthetists of Great Britain and Ireland, validated that Pall Ultipor(R) 25 Breathing System Filter retains prion proteins in a laboratory simulation of their clinical use in anesthesia.

Medical procedures in which patients share life-saving devices pose an especially high potential risk of cross infection. This may be problematic with prions due to their long incubation period where there are no signs or symptoms of disease and no tests to determine their presence in humans. It is current practice in certain anesthesia locales to reuse the breathing circuit between patients, when a filter is used at the patient end. The Pall Ultipor 25 Breathing System Filter is designed to protect breathing circuits and ventilators against patient cross contamination and has been validated against a host of pathogens.

"The presence of blood secretions in a high percentage of intubated anesthesia patients' airways presents a potential cross infection risk from prions as well as other agents," said Karen Wilkins, Director Scientific and Laboratory Services, Pall Medical. "This laboratory study specifically validates our breathing system filters against prions from entering the breathing circuit." The study was performed to test Pall Breathing System Filters for their specific ability to retain the abnormal form of prion proteins that have been found to be the causative agent of Transmissible Spongiform Encephalopathies (TSEs) in a simulation of their clinical use in anesthesia ventilation.

"These results are especially fortuitous with the new understanding that prions may be transmitted through blood," said Eric Krasnoff, Pall Chairman and CEO. "This research is just one step in Pall's ongoing commitment to provide the safest medical treatments possible and on our ongoing prion research program. Our prion research is also developing a filter to remove these rogue proteins from donor blood," he added.

Pall is currently involved in aggressive research programs using its proprietary technologies to remove prions from blood and to detect prions. The Company recently announced preliminary results of a study that found that a prototype leukocyte (white blood cell) reduction filter, containing new proprietary media, was effective in reducing infectious prions below the level of detection, specifically from scrapie-infected red blood cell concentrates. It plans on presenting results of this study at the International Society of Blood Transfusion later this year. Pall is also working on a system to detect prions in blood for early identification of infected animals before they manifest clinical signs or symptoms of disease and prior to their use as a food source.

Prions are the latest infective agent for which the Pall Ultipor 25 filter is validated to reduce. These breathing system filters are also validated against a host of bacterial and viral pathogens with a microbial rating of 99.999 percent using a monodispersed aerosol challenge, the most stringent in the industry. Its hydrophobic (repels liquids) media provides an absolute barrier to a liquid challenge, specifically secretions which include blood.

The Ultipor filter was recently recommended to help stop the spread of Severe Acute Respiratory Syndrome (SARS) in hospitals in both anesthesia and respiratory care. In June 2003, both the Taiwan Respiratory Society and the Ministry of Health and Long-Term Care in Ontario, Canada (two areas of the world hardest hit by SARS) recommended the use of high-efficiency breathing filters to help prevent disease transmission. They issued directives to use only filters that are hydrophobic and demonstrate high levels of viral retention to prevent contamination of equipment and cross contamination between patients.

Pall markets the Ultipor 25 filter worldwide for use in anesthesia. About 15 million surgical procedures are performed annually in Europe, and 45 million worldwide, where general anesthesia involving endotracheal intubation is employed. These procedures can range from minor surgeries, such as a tonsillectomy or removal of an ingrown toenail, to major operations such as orthopedic and cardiovascular surgery.

Prion Diseases

Prion diseases are fatal, neurodegenerative diseases, referred to as Transmissible Spongiform Encephalopathies (TSEs), that affect both humans and animals. They include scrapie in sheep, bovine spongiform encephalopathy in cattle and variant CJD in humans. It is estimated that the incubation period (prior to clinical symptoms) for variant CJD may be anywhere between 10 to 20 years. Since the first human case of vCJD was identified in 1994, there have been 154 confirmed cases worldwide with the vast majority (143) in the United Kingdom. On December 17, 2003, the Secretary of Health of the United Kingdom announced the first case of a patient dying from variant CJD received from a blood transfusion during an operation.

About Pall

Pall Corporation is the leader in the rapidly growing fields of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customer in biotechnology, pharmaceuticals, transfusion medicine, semiconductors, municipal drinking water, aerospace and broad industrial markets. Total revenues are $1.6 billion. The Company headquarters are in East Hills, New York with operations in more than 30 countries. Further information is available at www.pall.com.

This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current Company expectations and are subject to risk and uncertainties which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company's success in enforcing its patents and protecting its proprietary products and manufacturing techniques and its ability to achieve the savings anticipated from its cost reduction initiatives; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company's global markets. Additional information regarding these and other factors in available on the Web at www.pall.com and is included in the Company's reports filed with U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at www.sec.gov.

Editors Note:

Photos of the Pall Ultipor 25 Breathing System Filter and its use in anesthesia procedures with patients and a technical paper on the study methodology and results is available at www.pall.com/pressroom or by contacting P. Radowitz at 516 801 9124, e-mail: Pat_Radowitz at pall.com.

Interviews with Pall executives and researchers involved in the study are available on request.